Table 4 Respondents’ views on the acceptability of rationing an expensive cancer drug with different prospects of survival (Q6). N (%)
From: Attitudes towards priority setting in the Norwegian health care system: a general population survey
Fully disagree | Somewhat disagree | Neither agree nor disagree | Somewhat agree | Fully agree | Unanswered | Mean Likert score | N | |
|---|---|---|---|---|---|---|---|---|
2 months survival on average | 28 (8.0) | 27 (7.7) | 45 (12.9) | 126 (36.1) | 109 (31.2) | 14 (4.0) | 3.78 | 349 |
+ 5% long-term survival | 53 (15.1) | 70 (19.9) | 60 (17.0) | 100 (28.4) | 53 (15.1) | 16 (4.6) | 3.09 | 352 |
+ 15% long-term survival | 71 (21.5) | 78 (23.6) | 49 (14.8) | 90 (27.2) | 30 (9.1) | 13 (3.9) | 2.78 | 331 |